CRESTONE: Initial Efficacy and Safety of Seribantumab in Solid Tumors Harboring NRG1 Fusions - Episode 5

CRESTONE Trial of Seribantumab in NRG1+ Solid Tumors: Real-World Implications

July 20, 2022

Tejas Patil, MD, Alexander Spira, MD, PhD, FACP

Looking toward the future management of NRG1+ solid tumors, expert panelists consider how the availability of seribantumab therapy may impact their practice.

EP. 1: CRESTONE Trial of Seribantumab in NRG1+ Solid Tumors: Trial Design and Safety Data

EP. 2: CRESTONE Trial of Seribantumab in NRG1+ Solid Tumors: Efficacy Data

EP. 3: Duration of Seribantumab Therapy and Depth of Response in the CRESTONE Trial

EP. 4: Key Takeaways From the CRESTONE Trial of Seribantumab in NRG1+ Solid Tumors

Now Viewing

EP. 5: CRESTONE Trial of Seribantumab in NRG1+ Solid Tumors: Real-World Implications